PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6692351

Human brain tumor phosphoglycerides.

E Kökoğlu·G Güner·A Güner
View original source ↗Export metadata ↓

Abstract

This study is a qualitative and quantitative comparative analysis of the phosphoglycerides found in human brain tumors and normal brain tissue. Astrocytomas, glioblastomas, meningosarcomas and ependymomas were studied and, in all of these, the total phosphoglyceride levels were found to be significantly lower than in normal controls. Fractionation of the phosphoglycerides by thin-layer chromatography showed definite qualitative and/or quantitative differences in the phosphoglyceride fractions of tumor tissues in comparison with normal brain tissue.

Explore related subjects

Brain ChemistryBrain NeoplasmsGlycerophosphatesHumansJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Kökoğlu, G Güner, A Güner. 1984. Human brain tumor phosphoglycerides.. https://doi.org/10.1016/0304-3835(84)90012-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A subgroup of spinocerebellar ataxias defective in DNA damage responses.

A subgroup of human autosomal recessive ataxias is also characterized by disturbances of eye movement or oculomotor apraxia. These include ataxia telangiectasia (A-T); ataxia telangiectasia like disorder (ATLD); ataxia oculomotor apraxia type 1 (AOA1) and ataxia oculomotor apraxia type 2 (AOA2). What appears to be emerging is that all of these have in common some form of defect in DNA damage response which could account for the neurodegenerative changes seen in these disorders. We describe here sensitivity to DNA damaging agents in AOA1 and evidence that these cells have a defect in single strand break repair. Comparison is made with what appears to be a novel form of AOA (AOA3) which also shows sensitivity to agents that lead to single strand breaks in DNA as well as a reduced capacity to repair these breaks. AOA3 cells are defective in the DNA damage-induced p53 response. This defect can be overcome by incubation with the mdm2 antagonists, nutlins, but combined treatment with nutlins and DNA damage does not enhance the response. We also show that AOA3 cells are deficient in p73 activation after DNA damage. These data provide further evidence that different forms of AOA have in common a reduced capacity to cope with damage to DNA, which may account for the neurodegeneration observed in these syndromes.

Brain Chemistry↗